MC4R (Melanocortin-4 receptor)
also: MC4R, Melanocortin-4 receptor, MC4 receptor
Melanocortin-4 receptor, a hypothalamic GPCR involved in energy balance, sexual function and autonomic tone; with MC1R, one of two receptors the Vyleesi label calls most relevant for bremelanotide.
MC4R (Melanocortin-4 receptor) is a Gs-coupled class A GPCR expressed at high density in hypothalamic nuclei — particularly the paraventricular nucleus — and throughout the brainstem and spinal cord. It is the primary receptor through which alpha-MSH and related melanocortin peptides regulate energy homeostasis, sexual function, autonomic nervous system activity, and cardiovascular tone.
Why it matters in peptide research
MC4R holds a unique position in peptide research because it links two seemingly disparate domains: metabolic regulation and sexual function. Its role in energy balance is well established — MC4R mutations are the most common monogenic cause of human obesity, and the receptor mediates anorexigenic signals from the arcuate nucleus's POMC neurons that suppress appetite and increase energy expenditure. The central localization of MC4R in circuits linked to sexual motivation and arousal made it a candidate target for sexual dysfunction. The Vyleesi label says: "The mechanism by which VYLEESI improves HSDD in women is unknown." Its section 5.1 reports transient rises in blood pressure (up to 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose) and falls in heart rate (up to 5 beats a minute); the label contraindicates it in uncontrolled hypertension or known cardiovascular disease.
PDE5 inhibitors (sildenafil, tadalafil) act on vascular smooth muscle; melanocortin agonists are a different drug class. In a 2004 crossover study, men with erectile dysfunction and an inadequate response to Viagra had a significant erectile response to subcutaneous bremelanotide, which is not a labelled use (see the PT-141 page).
Peptides that act on this
- PT-141 (Bremelanotide) — a melanocortin receptor agonist that the Vyleesi label says "nonselectively activates several receptor subtypes with the following order of potency: MC1R, MC4R, MC3R, MC5R, MC2R", adding that "At therapeutic dose levels, binding to MC1R and MC4R is most relevant" and that "The MC1R is expressed on melanocytes; binding at this receptor leads to melanin expression and increased pigmentation." A 2022 review calls MC4R the most relevant subtype. It has a US label (Vyleesi) for hypoactive sexual desire disorder (HSDD) in premenopausal women; the label says it is not indicated in postmenopausal women or in men.
- Melanotan II — described in a 2020 case report as a non-selective melanocortin-receptor agonist; its small human studies tested pigmentation and erections, and no label for it was found in DailyMed or openFDA searches of 3 November 2026. FDA's page "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks" (content current as of 22 April 2026) is about compounding, meaning pharmacies preparing medicines from raw ingredients. It says: "Compounded drugs containing Melanotan II may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities. Published case reports discuss serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism." See the Melanotan II page.
Common misconceptions
MC4R agonists are sometimes categorized as "aphrodisiacs" — a term that implies enhancement of desire through a peripheral or non-specific stimulant mechanism. In reality, the compounds that act on MC4R also act on other melanocortin receptors, and how bremelanotide affects desire in women is, per its label, unknown. Nausea is the most common adverse reaction to bremelanotide: 40% of Vyleesi-treated patients in the pooled phase 3 trials, against 1% on placebo (US label). In a phase 4 trial of 228 healthy women, oral ondansetron taken 30 minutes before a dose did not reduce nausea, and the label says that pre-treatment is not recommended.
Related on this site
- PT-141 (bremelanotide) evidence summary
- Melanocortin receptor mechanism map
- PT-141 + Kisspeptin — combination evidence review
- MC1R (glossary)
- Correction (2026-11-06): Corrected 6 November 2026 after a dose and citation audit: unsourced claims that nausea is preventable, that MC4R acts dopamine-independently and that MC4R agonists work where PDE5 inhibitors fail were removed; the Vyleesi label's blood pressure and nausea findings and FDA's Melanotan II statement were added.
If you spot an error or have new evidence to suggest, please use our corrections policy.